Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

trastuzumab

Known as: Anti-p185-HER2, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-c-ERB-2 
A monoclonal antibody that binds to HER2 (human epidermal growth factor receptor 2), and can kill HER2-positive cancer cells. Monoclonal antibodies… Expand
National Institutes of Health

Related topics

Related topics

21 relations

Narrower (3)

ABP 980HerceptinPF-05280014
AC-T-T RegimenAntibody-Dependent Cellular CytotoxicityDrug AllergyERBB2 protein, human
Expand

Broader (1)

Antineoplastic Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
BACKGROUND There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and… Expand
Is this relevant?
Review
2019
Review
2019
Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy
During tumor progression, a subset of cancer cells escape from immune surveillance and eventually develop into measurable tumor… Expand
  • figure 1
  • figure 2
  • table 1
Is this relevant?
Review
2019
Review
2019
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study.
PURPOSE Nivolumab, an anti-programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Review
2019
Review
2019
Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
Targeted delivery of therapeutic molecules into cancer cells is considered as a promising strategy to tackle cancer. Antibody… Expand
Is this relevant?
Review
2018
Review
2018
Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
OBJECTIVE We conducted a phase I trial of neoadjuvant nivolumab, a monoclonal antibody to the programmed cell death protein 1… Expand
Is this relevant?
Review
2018
Review
2018
Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases
Anti-programmed cell death-1 (anti-PD1) antibodies are currently the first-line treatment for patients with metastatic BRAF wild… Expand
Is this relevant?
Review
2018
Review
2018
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Subcutaneous delivery of biotherapeutics has become a valuable alternative to intravenous administration across many disease… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2018
Review
2018
HER2-positive breast cancer: Current and new therapeutic strategies.
Since the identification of the HER2 receptor amplification as an adverse prognostic factor that defined a special subtype of… Expand
  • table 1
Is this relevant?
Review
2018
Review
2018
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors…
BACKGROUND The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study… Expand
  • figure 2
  • table 1
  • table 2
Is this relevant?
Review
2018
Review
2018
CAR T-cell Therapy: A New Era in Cancer Immunotherapy.
BACKGROUND Cancer is one of the leading causes of death worldwide. Over the years, a number of conventional cytotoxic approaches… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE